Opdivo plus Yervoy approved for mCRC
Bristol-Myers Squibb Co. (NYSE:BMY) said FDA granted accelerated approval to Opdivo nivolumab plus Yervoy ipilimumab to treat patients 12 years and older with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.
The approval was based on results from the Phase II CheckMate -142 trial in which the combination led to an overall response rate (ORR) of 49% in 119 patients with MSI-H or dMMR mCRC (see "BMS Reports Checkmate -142 Data for Opdivo Plus Yervoy in dMMR or MSI-H Metastatic CRC")...
BCIQ Company Profiles
BCIQ Target Profiles
Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152)